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Protein misfolding and amyloid formation - strategies for 
prevention 
Abstract 
Most proteins need to adopt a three-dimensional structure in order to function 
properly. Misfolding, or inability of proteins to fold, is associated with a number of 
diseases. In a subset of these disorders, the misfolded protein or peptide self-
assembles into stable, β-sheet rich structures known as amyloid fibrils. 
Alzheimer´s disease is associated with the aggregation of the amyloid β-peptide 
(Aβ) into oligomers and amyloid fibrils. Aβ has a discordant, i.e β-sheet preferring, 
helix prone to misfold and it has been proposed that stabilization of this helix could 
prevent aggregation. We have designed small molecules that bind to this region and 
stabilize Aβ in a helical conformation. This interaction reduced fibril formation and 
cell toxicity of the peptide and also restored a memory-linked electrophysiological 
function in mouse hippocampal slices treated with Aβ. Moreover, when 
administered orally, these compounds had a rescuing effect in a Drosophila 
melanogaster model of Aβ aggregation. 
Another protein capable of forming amyloid-like fibrils in association with 
disease, is the human lung surfactant protein C, SP-C, which has a discordant 
transmembrane helix. SP-C is expressed as a pro-protein with a C-terminal, CTC, 
which has a Brichos domain with unknown function. Here, we show that CTC is 
important for the stability and folding of the pro-protein in the endoplasmic 
reticulum (ER). It is able to prevent the mature SP-C from aggregating in vitro, and 
is shown to bind specifically to non-helical segments and to amino acids that have 
been reported to promote membrane insertion in the ER. Together these data 
suggest a chaperone function for CTC, targeting transmembrane regions that have 
not attained an α-helical conformation. CTC interacts with and reduces amyloid-
like fibril formation of Aβ as well as an additional amyloidogenic peptide – medin. 
In conclusion this thesis explores two new strategies for preventing protein 
misfolding and amyloid fibril formation. The first approach utilizes designed ligands 
to trap the Alzheimer´s disease associated Aβ in its native helical structure. The 
second employs a novel, natural chaperone that bridges folding of transmembrane 
regions and anti-amyloid properties. 
Keywords: protein misfolding, amyloid β-peptide, amyloid fibril, CTC, Brichos 
domain, chaperone 
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1  Introduction 
1.1  Protein folding and misfolding 
1.1.1  Protein folding and quality control 
Proteins are among the most important molecules in living organisms, 
constituting more than half the dry weight of a cell. There are 
approximately 20,500 protein-encoding genes in the human genome 
(Clamp et al., 2007) and these macromolecules take part in diverse processes 
such as food digestion and host defense. 
 
Proteins are made up of amino acid residues linked by peptide bonds. 
There are 20 naturally occurring amino acids and the order in which they 
occur in a polypeptide chain is referred to as a proteins primary structure. 
The primary structure, governed by environmental conditions, directs the 
folding of the polypeptide and the formation of secondary structure elements 
such as α-helices and β-strands. These elements are further arranged in space 
to produce the proteins functional 3D-structure; the tertiary and quarternary 
structure.  
 
Folding is a complex process still far from fully understood. There have 
been many attempts to predict the folding of proteins, some with great 
success such as the Rosetta algorithm (Das & Baker, 2008; Rohl et al., 
2004). However, no general solution, applicable to all proteins, has so far 
been achieved. Briefly, the driving force for correct folding is believed to be 
the search for the lowest possible energy state, a process that is governed by 
interactions within the molecules as well as between the molecule and the 
surrounding solvent. Each conformation that the protein can adopt is   12
associated with a free energy. Plotting free energies against their 
corresponding conformations generates an energy landscape on which the 
protein can fold on several pathways in its search for an energy minimum 
(Figure 1). During folding, proteins often form intermediate states, which 
are local minima in the energy landscape. The conformation with the lowest 
energy usually represents the native structure (Dobson, 2003; Dobson & 
Karplus, 1999). 
 
Figure 1. Energy landscape for protein folding, the unfolded (U), intermediate (I) and native 
states (N) are indicated. Adopted from (Tunnicliffe et al., 2005) with permission from the 
publisher.  
The paradigm stating that the function of a protein is determined by a 
unique 3D-structure is challenged by the existence of natively unfolded 
proteins. These proteins are mainly unordered but do contain some degree 
of secondary structure. Disordered proteins often function by binding to 
various partners, such as nucleic acids, and this interaction can induce 
folding of the unstructured protein. It is believed that the lack of stable 
structure could be a way of enabling the protein to have a broader binding-
specificity (Fink, 2005). 
 
The Levinthal´s paradox states that the number of possible conformations 
in the energy landscape for a polypeptide chain to adopt is extremely large. 
This would make it impossible for a protein to adopt all in a relevant time 
span in the search for the correct fold (Levinthal, 1968). One model put 
forward to explain this paradox is the hydrophobic collapse model (Dill et 
al., 1993). In this model, protein folding is believed to start by a   13
hydrophobic collapse, with the burial of hydrophobic residues in a folding 
core. Secondary and tertiary structures are then formed within this core with 
interactions such as disulfide bonds and salt bridges continuing to direct the 
folding, further helping in the choice of conformation. This model 
however, may not be applicable to transmembrane proteins since they will 
need to expose hydrophobic parts in order to be stable in the membrane 
environment. Another proposed mechanism is the nucleation-condensation 
model (Fersht, 1997).  According to this, secondary and tertiary structures 
form co-operatively as the whole protein condenses around a nucleus. This 
nucleus is formed by a few adjacent residues that have a high preference for 
early formation of secondary structure when stabilized by tertiary structure 
interactions. Together these types of constraints limit the number of 
available conformations and allow for the protein to fold in a biologically 
acceptable time span.  
 
The crowded environment in the cell, where the concentration of 
macromolecules can reach 400 mg/ml (Ellis & Minton, 2003), further 
complicates the folding process. When the unfolded polypeptide leaves the 
ribosome and enters the cytoplasm, or the endoplasmic reticulum (ER), its 
hydrophobic domains are exposed and the crowded environment may 
promote hydrophobic interactions between nascent proteins and other 
cellular components. The failure of a protein to fold properly or to retain its 
fold can lead to malfunction of vital cellular processes. In some cases 
misfolding results in harmful aggregation. To prevent these events a number 
of molecular systems have evolved to assist folding, one of them being the 
molecular chaperones (Ellis, 1990).  
 
Molecular chaperones provide a way of preventing aggregation and 
misfolding of newly synthesized proteins by maintaining them in a folding-
competent conformation. They interact with the nascent chains as they are 
emerging from the ribosomes or take part in later stages of the folding 
process. Chaperones do not increase the rate of folding but rather increase 
the efficiency by preventing un-wanted interactions. They perform their 
function by recognizing and binding to structures that are normally buried 
in the native state e.g. hydrophobic stretches and unstructured backbone 
regions, thereby shielding them from the surrounding. Chaperones are 
found in the cytosol but also in cellular compartments like the mitochondria 
and the ER. The class of molecular chaperones includes many families of 
proteins e.g. the heat-shock proteins, like Hsp70 and Hsp 40, as well as the 
large complexes called chaperonins. Hsps exert their function by binding   14
and releasing proteins in repeated cycles during the folding event until the 
protein has adopted a stable structure, whereas the chaperonins have a 
central cavity in which folding can occur protected from other molecules 
(Hartl & Hayer-Hartl, 2002; Frydman, 2001; Stevens & Argon, 1999; Hartl, 
1996). Recently, there have been reports suggesting that there are control 
mechanisms for folding in the extracellular space as well. These extracellular 
chaperones, including e.g. clusterin (Humphreys et al., 1999) and 
haptoglobin (Yerbury et al., 2005a), are upregulated during stress and have 
been shown to prevent stress-induced aggregation of a variety of proteins in 
vitro (Wilson et al., 2008). The function of these chaperones is not fully 
known but it has been suggested that they might mediate cellular uptake and 
subsequent degradation (Yerbury et al., 2005b). 
 
If a protein fails to adopt a stable fold or misfolds it can form aggregates, 
either amorphous or in some cases structured fibrillar forms (described in the 
following section). Under normal circumstances this is not a major problem 
since the cell has efficient ways of detecting and eliminating misfolded or 
unfolded species before they can induce any damage to the cell. Proteins 
that have failed in attaining their correct fold are recognized by a cytosolic 
enzyme that tags them with several ubiquitin molecules. This polyubiquitin 
tag then targets the protein to a large multiprotein assembly, called the 
proteasome, where it is subsequently destroyed (Hershko & Ciechanover, 
1998). Proteins that misfold in the ER are retro-translocated to the cytosol 
where they are then degraded by the same mechanism as described above 
(Meusser et al., 2005; Kopito, 1997).  
 
1.1.2  Amyloid fibrils 
Despite the many mechanisms nature has generated to prevent protein 
misfolding and aggregation there are a large number of diseases caused by 
the aberrant folding of proteins, so-called misfolding diseases. In a subset of 
these diseases proteins undergo conformational changes and self-associate 
into stable, insoluble, aggregates with β-sheet structure called amyloid fibrils. 
These structures are highly protease resistant and the cell is often unable to 
degrade them. All amyloid fibrils are composed of β-sheets with their 
constituent hydrogen bonded strands, parallel or anti-parallel, running 
perpendicular to the axis of the fibril (Figure 2). This cross-β structure was 
first observed by X-ray diffraction (Eanes & Glenner, 1968), where amyloid 
fibrils show two distinct signal, one at 4.7 Å and one between 10-11 Å. The 
4.7 Å signal corresponds to the hydrogen bonding distance between the   15
strands in each sheet and the other signal indicates the spacing between 
different interacting sheets. Recently, methods like solid-state NMR 
((Tycko, 2006) and references therein) and cryo-electron microscopy 
(Serpell & Smith, 2000) have further helped in characterizing the fibril 
structure from a number of proteins. Mature fibrils are usually made up of 2-
6 fibrillar subunits named protofilaments which, slightly twisted around each 
other, form unbranched fibers, 7-12 nm in diameter (Makin & Serpell, 
2005). In order to be called amyloid, certain criteria has to be met. 
Depositions has to occur in vivo, the fibrils should be straight and 
unbranched and show the typical X-ray diffraction as mentioned above. In 
addition, staining with the dye Congo red should result in green 
birefringence in polarized light. Fibrils formed in vitro are referred to as 
amyloid-like fibrils. 
 
Figure 2. Protein folding and misfolding. Proteins fold and unfold continuously during their 
lifespan. It is believed that amorphous, unstructured aggregates can form from unfolded as 
well as partially unfolded states. Structured aggregates most likely form from partially 
structured intermediates. These aggregates can go on to form amyloid-like fibrils. These 
insoluble fibrils are composed of β-sheets parallel to the fibril axis and are usually made up of 
2-6 protofilaments, twisted around each other. (Fibril model adapted from (Jimenez et al., 
1999)) 
There are today 28 known amyloid forming proteins and peptides in 
man (Benson et al., 2008; Westermark et al., 2007). These proteins, 
including e.g. the amyloid β-peptide associated with Alzheimer’s disease, the 
islet amyloid polypeptide which aggregates in type II diabetes and the prion 
protein in Creutzfeld-Jakob disease, do not share any obvious sequence 
identities but form fibers with similar morphology. These observations   16
together with the finding that a large number of proteins not associated with 
amyloid disease can form amyloid-like fibrils under certain conditions, has 
led to the suggestion that amyloid fibril might be a generic conformation 
that all proteins could adopt (Stefani & Dobson, 2003). Most proteins 
however do not form fibrils under physiological conditions, but require 
harsh treatments in order to do so. Sawaya et al. recently proposed that the 
core of amyloid fibrils is a steric zipper and that the ability to form these 
zippers is highly sequence dependent (Sawaya et al., 2007). Main 
determinants for fibril formation has been reported to include charge, 
hydrophobicity and secondary structure propensity (Chiti et al., 2003). The 
conformational stability (Ramirez-Alvarado et al., 2000; Kelly, 1996), as well 
as the solubility of the folded conformation, is also important for its ability to 
form fibrils, with fibril formation being most prominent at the pI of the 
protein (Schmittschmitt & Scholtz, 2003). π–stacking of aromatic residues 
has also been implicated to play an important role (Tartaglia et al., 2004; 
Gazit, 2002). Amyloid diseases are classified as either localized, when only 
one organ is affected e.g. the brain in Creuztfeld-Jakob disease, or systemic if 
deposits are found in a wide range of tissues and organs e.g. lysozyme 
amyloidosis. 
 
For amyloid fibril formation to occur the native protein needs to be 
destabilized in order for aggregation to take place. It is believed that 
amorphous aggregates can from both unfolded and intermediate states 
whereas structured aggregates like amyloid fibrils most likely originates from 
partially folded intermediates (Figure 2). The formation of amyloid fibrils is 
a nucleation-dependent process. This type of process is characterized by; a 
critical concentration below which no aggregation will occur, a lag phase when 
oligomers (nucleus) are formed from un/misfolded monomers by a series of 
thermodynamically unfavorable steps, followed by a more rapid elongation 
phase and finally a steady state phase where monomers and fibrils are at 
equilibrium (Figure 3). The lag phase can be abolished by adding a preformed 
nucleus, a so-called seed. It has been suggested that the fundamental unit of 
all amyloid fibrils is a dry steric zipper formed by two tightly interdigitated 
β-sheets (Sawaya et al., 2007). The process of fibril formation then probably 
starts by the un-masking of several zipper-forming segments, permitting 
them to stack into sheets – if this is a naturally occurring event it would be 
compatible with the slow nucleation event.    17
 
Figure 3. Formation of amyloid fibrils is a nucleation dependent process. This type of event is 
characterized by a slow lag-phase, followed by an elongation phase and finally a steady-state 
phase. 
In contrast to the disease-associated amyloids, amyloid formation is 
sometimes utilized by nature for beneficial functions. Two examples of these 
functional amyloids are the human protein Pmel17 (Berson et al., 2003) 
which forms amyloid important for skin and eye pigmentation and the 
amyloid fibrils called curli that are involved in cell-cell contacts of Escherichia 
coli (Chapman et al., 2002).  
1.2  Alzheimer´s disease 
1.2.1  General introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder named 
after the German physician Alois Alzheimer who first described the disease 
in 1907 (Alzheimer, 1907). AD is the most common cause of dementia in 
elderly, accounting for 60-70% of all cases (Fratiglioni et al., 2000). Age is 
the strongest risk factor for AD, the prevalence for the disease is around 1% 
at age 65 and around 20% at age 85 (Ferri et al., 2005). Together with the 
growing elderly population in the world the number of people affected by 
AD is expected to increase enormously and with it the cost for society.  
 
The two major neuropathological hallmarks of AD are extracellular 
deposits called senile plaques and intracellular neurofibrillar tangles (NFTs). 
NFTs are composed of paired helical filaments of hyperphosphorylated tau 
(Grundke-Iqbal et al., 1986), a microtubule-binding protein, and are 
believed to form after the senile plaques (Hardy et al., 1998), which are 
mainly composed of amyloid fibrils formed by the amyloid β-peptide (A  β)  18
(Masters et al., 1985; Glenner & Wong, 1984). Aβ is an enzymatic cleavage 
product generated from the amyloid-β precursor protein, and its aggregation 
is believed to be the major cause of the disease (Hardy & Selkoe, 2002). 
 
The first symptoms of AD are often loss of short-term memory and as the 
disease progresses, disorientation, aphasia and a general decline in cognitive 
functions follows. Even though there are different tests and criteria available 
for clinical diagnosis, a definite AD diagnosis can only be made post mortem 
by a pathological exam of the brain to verify the existence of the above 
mentioned neuropathological lesions. 
 
Patients suffering from the disease are usually divided into two subgroups 
based on age of onset. Early onset AD, which accounts for about 2 % of all 
AD cases, appears before the age of 65 whereas the more common form, late 
onset AD, called sporadic (SAD), have an onset after 65 years of age. 
Familial AD (FAD) belongs to the group of the early-onset AD and is 
caused by mutations in amyloid-   precursor protein, Presenilin 1 or
Presenilin 2 (which are  discussed below). 
 
1.2.2  Amyloid-β precursor protein and the amyloid β-peptide 
Amyloid-β precursor protein (APP) is a type I transmembrane protein, with 
its N-terminal end in the extracellular space, ubiquitously expressed in a 
variety of cells types (Mattson, 1997). There are three main isoforms of the 
protein found in the brain, APP695, APP751 and APP770, where APP695 is the 
predominant form expressed in neurons (Kitaguchi et al., 1988; Ponte et al., 
1988; Tanzi et al., 1988; Kang et al., 1987). The role of APP is still 
unknown but a number of functions have been suggested, see (Thinakaran 
& Koo, 2008). Initially it was believed to be a cell surface receptor, it has 
been implicated to play a role in cell adhesion and also to have a trophic 
role, the latter function is compatible e.g. with the finding that APP is up-
regulated during neuronal maturation (Hung et al., 1992). A study by Kamal 
et al. suggested that the protein might be involved in axonal vesicle transport 
(Kamal et al., 2001). A recently proposed function of APP as a ligand for the 
death receptor DR6 in neurons potentially links APP to Alzheimer´s disease. 
The study shows that an N-terminal fragment of APP is released upon 
trophic depravation, binds to DR6 and thereby triggers degeneration of 
neural cell bodies and axons (Nikolaev et al., 2009). 
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APP is sequentially cleaved by proteases in two distinct pathways (Figure 
4) (Esler & Wolfe, 2001). The so-called amyloidogenic pathway generates 
the amyloid β-peptide (Aβ), a peptide of predominantly 40-42 amino acid 
residues associated with amyloid formation and AD. In the predominant 
non-amyloidogenic pathway α-secretase cleaves APP within the Aβ region 
between residue 16 and 17 (Parvathy et al., 1999; Sisodia, 1992; Esch et al., 
1990), releasing a large soluble fragment, αAPPs, and creating a membrane 
bound fragment, C83. C83 is then further cleaved by γ–secretase in the 
transmembrane region yielding the extracellular peptide p3 and the 
intracellular AICD (Haass et al., 1993). γ–Secretase takes part in both the 
amyloidogenic and the non-amyloidogenic pathways and is a membrane 
associated enzyme complex made up of presenilin 1 or 2, Pen-2, Aph-1 and 
nicastrin (De Strooper, 2003). Mutations in the presenilins cause increase in 
production of Aβ1-42 and are linked to FAD (Czech et al., 2000). In the 
amyloidogenic pathway the first cleavage is performed by β-secretase 
(BACE1)(Vassar et al., 1999) at the N-terminal end of the Aβ region 
generating C99 and the soluble N-terminal fragment βAPPs. Subsequent γ–
secreatse cleavage of C99 produces Aβ. The γ–cleavage is a heterogeneous 
event leading to the formation of Aβ species with various lengths. The 
predominant species are Aβ1-40 and the more aggregation prone Aβ1-42 
(Naslund et al., 1994), but species of 38-43 residues have been observed. 
 
Figure 4. APP processing follows two main pathways; the non-amyloidogenic, generated by 
α- and γ-secretase cleavage, and the amyloidogenic, generated by β- and γ-secretase cleavage. 
The later pathway produces the amyloid β-peptide.   20
The Aβ segment corresponds to residue 596-636(8) of APP and contains 
a part of the transmembrane region, residues 625-638 (residues 29-42 of 
mature Aβ). The Aβ sequence is shown below: 
 
 
D1AEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV40IA42 
 
 
The Aβ peptide has a hydrophobic C-terminal and a hydrophilic N-
terminal. It is disordered in water solution but deviates from a complete 
random conformation by a few non-random regions (Figure 5A). NMR 
studies have indicated a turn-like structure at residue 8-12 and hydrophobic 
interactions between side-chains in the 16-24 regions with a bend-like 
structure at 20-24 (Riek et al., 2001). The secondary structure of 
monomeric Aβ1-40 and Aβ1-42 is very similar even though their aggregation 
behavior is different. This difference could perhaps be explained in part by 
the finding that the C-terminal end of Aβ1-42 is more rigid than that of Aβ1-40 
(Yan & Wang, 2006; Riek et al., 2001) and that it shows β-strand tendency 
in the regions 31-36 and 39-41 (Hou et al., 2004).  
 
In membrane mimicking solutions Aβ adopts more stable secondary 
structures. In the presence of SDS micelles, Coles et al. showed the presence 
of two helices at positions 15-24 and 28-36 in Aβ1-40 (Coles et al., 1998). A 
more recent study confirmed this, indicating two helices covering the 
regions 15-24 and 30-35, with the first helix interacting with the micelle 
surface and the second one buried inside the hydrophobic interior (Jarvet et 
al., 2007) (Figure 5B, C). The helix covering residue 16-23 is discordant, 
i.e. it is predicted to form a β-strand but shows a helix conformation in 
experimental determined structures (Kallberg et al., 2001). Using structure-
inducing organic solvents, more stable secondary structures are also reported 
but with slightly different locations. Crescenzi et al. showed helices at 8-25 
and 28-38 connected by a β-turn in Aβ1-42 using hexafluoro-isopropanol 
whereas Sticht et al. indicated the presence of helices in Aβ1-40 covering 
regions 15-23 and 31-35 with a disordered region in-between in 
trifluoroethanol (Crescenzi et al., 2002; Sticht et al., 1995). In complex with 
the affibody protein ZAβ3, Aβ1-40 forms a β-hairpin, with residues 17-23 and 
30-36 forming β-strands, that is similar, although the orientation of the 
hydrogen bonds are shifted 90º, compared to that found in mature fibrils 
(Hoyer et al., 2008). 
   21
 
Figure 5. Models of Aβ1−40 monomer in different solutions. A) Model structure of Aβ1-40 in 
water. Twenty calculated structures, obtained by NMR constraints, are superimposed over 
residues 16-24 and indicate that this region contains non-random structure. From (Riek et 
al., 2001) with permission from the publisher. B) Model of Aβ1-40 in SDS micelles. 
Superimposition of residues 15-24 reveals two helices (15-24 and 28-36) with varying 
orientation relative to each other. From (Coles et al., 1998) with permission from the 
publisher. C) Suggested positioning of membrane-associated Aβ. The barrels correspond to 
two helices; one in the region 15-24 positioned superficially and the other, 29-C-terminus, 
buried in the hydrophobic interior of the membrane. Adapted from (Coles et al., 1998) and 
(Jarvet et al., 2007). 
It is believed that Aβ leaves the membrane upon cleavage but it has also  
been suggested that it might stay and exert its toxicity from there (Marchesi, 
2005). Lundin et al. have shown that the ability of Aβ peptides to stay 
inserted in membranes is strongly correlated with their length and ability to 
adopt a helical structure (Lundin et al., 2007). In their study a minimum of 
46 residues was needed for membrane retention. This implies that Aβ1-40 as 
well as Aβ1-42 would be released from the membrane upon cleavage by γ-
secretase. The release from the hydrophobic environment in the membrane, 
which probably stabilizes the helical structures, into the hydrophilic 
surrounding could increase the aggregation rate and fibril formation of the 
peptide. 
 
1.2.3  Amyloid fibrils and oligomers 
Aβ forms fibrils that are deposited in the brains of affected patients in so-
called plaques. The dominating Aβ specie in the plaques is Aβ1-42 (Iwatsubo 
et al., 1994). The identification of Aβ and its correlation to AD, led to the 
development of the amyloid cascade hypothesis in 1992 (Hardy & Higgins, 
1992). In this first version, the insoluble Aβ fibrillar deposits were 
considered to be causative of disease triggering pathogenic processes leading   22
to neuronal death and synaptic dysfunction. However, poor correlation 
between number of plaques and severity of disease has resulted in a revised 
version which includes soluble oligomers (Hardy & Selkoe, 2002). The level 
of soluble Aβ species correlates better with disease (Lue et al., 1999; McLean 
et al., 1999) and they are now believed to be the main cause of 
neurodegeneration.  
 
Since fibrils were earlier believed to be the major disease-causing 
assemblies, much effort has been made to determine the structure of fibrils 
formed by Aβ1-40 and Aβ1-42 as well as by shorter fragments. It has been 
shown that fibrils formed under different conditions vary in their 
morphology (see e.g. (Kodali & Wetzel, 2007; Paravastu et al., 2006; 
Goldsbury et al., 2000)) but the same conditions can also give rise to a 
polymorphic population of fibrils (Meinhardt et al., 2009). Solid state NMR, 
atomic force microscopy and transmission electron microscopy have been 
used to show that different fibril morphologies have different molecular 
structure indicating multiple assembly pathways (Goldsbury et al., 2005; 
Petkova et al., 2005). A possible explanation as to why fibrillar deposits and 
disease do not correlate, besides the oligomer theory, could be that only 
some of the possible fibril morphologies are actually harmful. It has, for 
example, been shown that fibrils formed without agitation are more toxic to 
primary rat embryonic hippocampal neurons in vitro than agitation induced 
fibrils (Petkova et al., 2005). It is important to keep in mind that the studies 
on fibrils are almost exclusively carried out on fibrils formed in vitro. 
Whether or not all or some of the various morphologies described actually 
exist in an in vivo situation, or are just artifacts of the experimental 
conditions used, still remains to be seen. 
 
Aβ1-40 fibrils are made up by in-register parallel β-sheets (Balbach et al., 
2002; Petkova et al., 2002) but fibrils grown with gentle agitation differ 
morphologically and in overall symmetry from fibrils grown under quiescent 
conditions. Two structural models have been developed using solid state 
NMR and electron microscopy and propose that protofilaments of 
agitation-induced fibrils are composed of two stacked layers of Aβ molecules 
whereas quiescent fibrils have three molecular layers in threefold symmetry 
around the fibril axis (Paravastu et al., 2008; Petkova et al., 2006) (Figure 
6A, B). The β-strands in agitated fibrils are made up of residues 10-22 and 
30-40 with a bend or loop in between. A stabilizing intermolecular salt 
bridge is formed between D23 and K28 and a hydrophobic cluster 
(L17/F19/I32/L34/V36) stabilizes the fold of a single layer. The   23
intermolecular side chain interactions are formed between the odd-
numbered residues in strand β1 on the nth molecule and the even-
numbered residues of strand β2 in the (n±2)th molecule. Interactions 
between layers are found between the side chains of I31 and M35 and the 
backbone of G37 and G33 (Petkova et al., 2006). In quiescent fibrils, the β-
strands are made up of residues 11-22 and 30-40. The D23-K28 saltbridge is 
not always present and the fold of a single layer is stabilized by 
H13/F19/I32/V36/V40 hydrophobic contacts. I31 and V39 form contacts 
between layers (Paravastu et al., 2008).
 
  
 
Figure 6. Proposed models for protofilament arrangement in Aβ1-40 fibrils. A) Fibrils formed 
under agitation forms two-layer protofilaments. From (Petkova et al., 2006). B) Fibrils 
formed under quiescent conditions show a three-fold symmetry around the fibril-axis. From 
(Paravastu et al., 2008) with permission from the publisher.  
Aβ1-42 fibrils are also composed of in-register parallel β-sheets (Antzutkin 
et al., 2002) and resemble agitated Aβ1-40 fibrils. A recent model for Aβ1-
42(M35ox) fibrils however, indicates differences compared to the one 
proposed for Aβ1-40 fibrils (Luhrs et al., 2005). In this model, residues 1-17 
are disordered and the β-strands are made up of residues 18-26 and 31-42. 
The intermolecular saltbridge between D23 and K28 is present but all 
intermolecular side chain interactions are formed between the odd-
numbered residues in strand β1 on the nth molecule and the even-
numbered residues of strand β2 in the (n-1)th molecule (Figure 7). This 
conformation, like that of Aβ1-40 fibrils, would leave partially unpaired β-
strands at each end of the fibril which could explain the sequence-specific 
co-operative mechanism of fibril extension. Another difference compared to 
models of Aβ1-40 fibrils is that the protofilaments of Aβ1-42 fibrils consist of a 
single layer of molecules.  
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Figure 7. Model of Aβ1-42 fibril indicating the amino acid residues making up the β-strands (A) 
and the orientation and offset of the strands in the fibril (B). From (Luhrs et al., 2005) with 
permission from the publisher. 
Recently, focus has been shifted from mature fibrils to soluble oligomers 
and early aggregates. These smaller aggregates are now believed to be the 
more toxic species which could explain the weak correlation between 
fibrillar deposits and severity of disease (Terry et al., 1991). A number of 
different soluble assemblies, both on- and off-pathway, have been described 
ranging from dimers to larger aggregates of a few hundred kDa. There are 
few molecular structures of these aggregates, two published structures 
indicate β-sheet content  but with different orientation of the strands (Yu et 
al., 2009; Chimon et al., 2007), which make them hard to classify and 
characterize. It is also possible that the choice of analytical method used for 
the identification can influence the structure of the oligomers. Hence, it is 
possible that some of the oligomers described in the literature are in fact 
variants of the same assembly. The study of aggregation in vitro is also 
associated with differences in protocols for solubilizing the Aβ peptide as 
well as small variations between different batches of synthetic peptide. Taken 
together all these factors further complicate the study of Aβ and its role in 
AD. 
 
Protofibrils are the largest oligomers described and considered to be true 
intermediates in the assembly of Aβ fibrils, since they go on to form mature 
fibrils and can dissociate into monomers. They are shorter (< 200 nm) and 
somewhat thinner than mature fibrils and have been shown to be neurotoxic 
and to interfere with electrophysiological mechanisms associated with 
memory (Hartley et al., 1999; Walsh et al., 1999; Harper et al., 1997; Walsh   25
et al., 1997). Other, non-fibrillar, soluble oligomers have been identified by 
several groups.  
 
Amyloid-β-derived diffusible ligands (ADDLs) were first reported on by 
Oda et al. when they found small Aβ complexes in solutions of Aβ1−42 co-
incubated with ApoJ (clusterin) (Oda et al., 1995). These complexes were 
thereafter shown by Lambert et al. to be low molecular weight oligomers 
around 17-27 kDa that where neurotoxic and could inhibit long term 
potentiation (LTP) in rat hipoocampal slices (Lambert et al., 1998). A recent 
study combining analytical ultracentrifugation with size-exclusion 
chromatography (SEC), indicated that this might in fact be a more 
heterogenous group than first proposed with sizes ranging from monomers 
up to 200 kDa (Hepler et al., 2006). ADDLs have been isolated from AD-
affected brains and found to be present in higher levels in disease brains 
compared to controls (Gong et al., 2003). Globulomers, Aβ1−42 12-mers 
possibly arranged in a micelle-like manner with the C-terminals of the 
peptides buried in the middle, are another reported oligomer that can block 
LTP. They have been found in brains of AD-patients and can also be 
prepared in vitro in the presence of SDS where they form independently 
from fibrils (Gellermann et al., 2008; Barghorn et al., 2005). Recently much 
attention was given a soluble SDS-stable 56-kDa Aβ assembly named Aβ*56 
(Lesne et al., 2006). This oligomer was isolated from brains of APP 
transgenic mice and found to be the cause of long term memory 
impairment. This negative effect on memory was also evident when Aβ*56 
was administered to healthy, young rats. Annular Aβ assemblies have been 
found in in vitro experiments and in cell culture and have led to the channel 
hypothesis, suggesting that Aβ may form pore-like membrane-disrupting 
species (Quist et al., 2005; Lashuel et al., 2002). 
 
Low-n SDS-resistant oligomers, dimers up to tetramers, can be secreted 
by cultured cells and have been isolated from human brain and cerebrospinal 
fluid (Walsh et al., 2000; McLean et al., 1999; Podlisny et al., 1995). When 
injected into rat brains they inhibit LTP (Walsh et al., 2002). Recently, Aβ 
dimers were extracted from human AD brains (Shankar et al., 2008) and 
shown to inhibit LTP in mice hippocampal slices as well as to impair 
memory of healthy rats. Together these data further support the emerging 
picture of small, soluble assemblies as main synaptotoxic agents.  
 
Since the aggregation of Aβ is a dynamic process it is likely that the 
population of different assemblies will vary from time to time both in vitro   26
and in vivo. This will further complicate the issue of determining which the 
true toxic species are. A large number of the described oligomers are 
generated in vitro and how all these different oligomers correlate to the in 
vivo situation is still unknown. 
  Model systems for Alzheimer´s disease in vivo 
There is a wide gap between the numerous in vitro studies on the 
aggregation and toxicity of Aβ and the actual pathogenesis of AD. In order 
to overcome this problem a number of AD animal models have been created 
to gain better understanding of the underlying mechanisms and possible 
treatments. None of these models can correctly mirror all characteristics of 
the disease observed in humans, but they are valuable tools that allows the 
study of specific aspects of the disease. The most common model animal is 
the mouse and there are several established transgenic mouse models 
available (Gotz & Ittner, 2008; Woodruff-Pak, 2008). The most common 
ones express human APP with one or more mutations, such as the Swedish 
mutation (K670N/M671L, Tg2576 mice) which causes overproduction of 
Aβ by increased β-secretase cleavage. Secretase models in which γ-secretase 
activity is altered, favoring production of Aβ1-42, are also used. The model 
that closest reflects human AD pathology, so far, is the 3xtg-AD mouse that 
expresses mutant human APP, tau and presenilin 1 (Oddo et al., 2003). 
These mice show plaque formation, neuronal loss, memory impairment and 
the formation of neurofibrillar tangles.  
 
Invertebrate models, using the nematode Caenorhabditis elegans and 
particularly the fruit fly Drosophila melanogaster, have emerged as powerful 
tools to explore the mechanisms of neurodegenerative disease and for drug 
screening (Link, 2005).  Almost 70% of human disease related genes have 
homologues in Drosophila (Reiter et al., 2001; Fortini et al., 2000), 10% of 
which are involved in neurological disease (Greenspan & Dierick, 2004). 
Even though fruit flies have different neuroanatomical organization, the 
basic cell biology and the major neurotransmitter systems are well conserved 
(Iijima & Iijima-Ando, 2008), making them useful for modeling molecular 
and cellular processes underlying AD. Several groups have described AD 
models using D. melanogaster. The flies have a neuron-specific APP homolog 
(Appl) which however lacks the Aβ region, but a functional γ-secretase 
homolog exists. Some groups express human Aβ (1-40 or 1-42) in the CNS 
and retina of the flies (Crowther et al., 2005; Finelli et al., 2004; Greeve et 
al., 2004; Iijima et al., 2004) whereas others (Greeve et al., 2004) have 
expressed human APP together with BACE1 to study APP processing, in   27
addition to Aβ toxicity. These models all exhibit reduced lifespan, 
neurodegeneration and behavioral deficits correlated to Aβ aggregation. 
Thioflavin S positive, amyloid plaque formation was seen in flies expressing 
Aβ1-42. The short lifespan and short generation times of D. melanogaster 
together with their low cost also make these model systems useful for large 
drug screens (Crowther et al., 2006).  
1.3  Amyloid prevention strategies in Alzheimer´s disease 
Protein misfolding diseases for which there are no cures, e.g. Alzheimer’s 
disease, is a growing problem and finding therapeutic strategies to prevent or 
treat these disorders is a challenging and important task. A lot of efforts have 
been made in this field and the current strategies include (i) decreasing 
production of the amyloidogenic protein/peptide, (ii) preventing or altering 
aggregation or misfolding using low molecular weight compounds and (iii) 
neutralizing or removing misfolded, toxic species. These seemingly 
straightforward approaches have so far not been very successful.  
 
In the case of AD, no effective therapies have emerged even though a 
large number are currently in clinical trials. There are today no available 
treatments that modify the disease progression, only symptomatic treatments. 
One example of a cognitive enhancer used to treat dementia symptoms are 
the acetylcholinesterase inhibitors. These compounds increase the levels of 
the neurotransmitter acetylcholine in synapses but do not affect any 
underlying cause of disease. Another available form of treatment is the N-
methyl-D-aspartate (NMDA) receptor antagonist, memantine (Chen & 
Lipton, 2006). Some of the efforts in finding AD therapeutics are briefly 
summarized below.   
 
1.3.1  Targeting Aβ production 
Aggregation of Aβ is concentration dependent, so one possible way of 
targeting AD pathogenesis would be to inhibit β− or γ-secretase and thereby 
reduce Aβ formation. β-Secretase seems a promising target since it is the 
rate-limiting enzyme in Aβ production, its structure has been solved (Hong 
et al., 2000) and it seems to have a more narrow substrate specificity than γ-
secretase. However, the active site of the protease has proved to be very 
large, making inhibitor design challenging and very few reports on inhibitors 
that bind and reduce β-secretase activity exist (Ghosh et al., 2008; Hussain et 
al., 2007). γ-Secretase inhibitors that reduce Aβ synthesis have been   28
identified and are being tested in humans (e.g. (Fleisher et al., 2008)). A 
problem with this approach would of course be the of β- and γ-secretase in 
other cellular processes. γ-Secretase has numerous substrates and cleaves for 
example the Notch receptor (Hartmann et al., 2001), important for cell 
differentiation, and β-secretase has been suggested to be important for nerve 
myelination (Hu et al., 2006).  Consequently, finding ways of altering the 
activity of these enzymes rather than completely blocking them could prove 
more beneficial. Substrate-targeting γ-secretase modulators, e.g. some non-
steriod anti-inflammatory drugs (NSAIDs), have been shown to affect the 
production of Aβ by binding to APP in the Aβ region and thereby 
modulate  γ-secretase cleavage and the levels of released Aβ1-42 (Kukar & 
Golde, 2008; Kukar et al., 2008). This approach does not affect the activity 
of γ-secretase on other substrates, but is only applicable provided that APP 
or its cleavage products are not essential for any cellular functions. 
 
1.3.2  Amyloid clearance - immunotherapy 
One strategy that has been explored for Alzheimer´s disease, and that could 
prove to be beneficial both for prevention and treatment, is the concept of 
immunotherapy. Schenk et al (Schenk et al., 1999) introduced the idea by 
showing that immunization with Aβ1-42 could prevent amyloid formation in 
brains of young mice and also reduce the plaque burden in older mice that 
already had developed AD pathology. This finding was confirmed by several 
studies and it was also shown that passive immunization had equally positive 
effects (Bard et al., 2000). A human trial was initiated using an Aβ1-42 
immunization protocol (Bayer et al., 2005) but was terminated early due to 
the development of meningoencephalities in 6% of the treated patients 
(Nicoll et al., 2003; Orgogozo et al., 2003). The results of the few post 
mortem studies available on immunized patients show a reduction of plaques 
compared to the control group (Nicoll et al., 2006). Currently, a number of 
new trials with hopefully safer vaccines are ongoing using both passive and 
active immunization (Nitsch & Hock, 2008). The mechanisms behind the 
effects seen with Aβ antibodies are unclear but proposed modes of action 
include the sink hypothesis (DeMattos et al., 2001), where the antibody in 
plasma is believed to extract Aβ from the brain, as well as the idea that the 
antibodies will pass into the brain and aid in the clearance of plaques by for 
example inducing microglial-mediated phagocytosis (Schenk et al., 1999).  
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1.3.3  Inhibition of misfolding and fibril formation 
Chaperones 
Molecular chaperones provide a first line of defense against protein 
misfolding and self-assembly in the cell, as described above in section 1.1. 
To utilize this protection system by enhancing chaperone activity could be a 
useful therapeutic approach. A number of Hsps, such as Hsp90 and the 
combination of Hsp 70 and 40, have been shown to effect Aβ1−42 fibril 
formation at an early stage (Evans et al., 2006). Hsps play important roles 
also in other misfolding disorders, e.g. Hsp70 has effect on α-synuclein 
aggregation (Dedmon et al., 2005). Hsp104 suppresses fibril formation of 
Aβ1-42 by interacting with various species on the fibrillization pathway and 
also has an amyloid-disaggregation ability in vitro towards Sup35-fibrils 
(Arimon et al., 2008; Shorter & Lindquist, 2004).  
The Hsps function intracellularly but an extracellular chaperone, 
apolipoprotein J also called clusterin, that inhibits amorphous aggregation of 
various proteins has been found to inhibit fibril formation of a number of 
proteins such as Aβ and α-synuclein (Yerbury et al., 2007; Humphreys et al., 
1999; Matsubara et al., 1996). It was proposed that the chaperone interacts 
with structural features common to pre-fibrillar species. 
Up-regulation of molecular chaperones has proved possible using a 
pharmacological approach. For example, an Hsp90 inhibitor has been found 
to up-regulate Hsp70 and suppress Aβ-induced neurodegeneration in a cell 
model (Ansar et al., 2007). A delicate balance of chaperones will be required 
for beneficial effects. So far, no effective treatment utilizing this natural 
defense has been found. 
 
Low molecular weight inhibitors 
Small organic molecules have been found to interfere with the aggregation 
of Aβ. Some of the inhibitor compounds reported on include: Congo red, 
curcumin, melatonin, nicotine, rifampicin, methylene blue, scyllo-inositol, 
indole derivatives, RS-0406 and β-cyclodextrin (Necula et al., 2007; Cohen 
et al., 2006; Yang et al., 2005; Nakagami et al., 2002; McLaurin et al., 2000; 
Pappolla et al., 1998; Podlisny et al., 1998; Salomon et al., 1996; Tomiyama 
et al., 1996; Camilleri et al., 1994). These compounds are not similar in 
structure, though they are often aromatic and/or hydrophobic, and probably 
act in different ways and at different stages of aggregation. For example, 
nicotine was reported to reduce fibril formation by interacting with and 
possibly stabilizing the helical structure of Aβ (Salomon et al., 1996). RS-
0406 was found in a screen of > 100,000 compounds and shown to inhibit   30
fibril formation, reduce Aβ-induced cell toxicity as well as rescue long term 
potentiation (Nakagami et al., 2002). Scyllo-inositol, a naturally occurring 
molecule, has been shown to alter Aβ1−42 aggregation, possibly by binding to 
low molecular weight oligomers and is being tested in clinical trials 
(Townsend et al., 2006; McLaurin et al., 2000). When administered to AD 
transgenic mice the compound improved cognition and reduced soluble 
levels of both Aβ1−40 and Aβ1−42 as well as Aβ depositions in the brain 
(McLaurin et al., 2006). 
 
One small-molecule inhibitory approach has been to target agents 
suggested to interact with Aβ and to promote fibril formation. 
Glycosaminoglycans (GAGs) have been implicated as mediators of Aβ fibril 
formation (McLaurin et al., 1999). Amino-propane-sulfonic acid, APS, also 
called tramiposate, was designed to compete with GAGs in their binding to 
Aβ. This compound prevents Aβ aggregation and is currently in phase III 
clinical trials (Barten & Albright, 2008; Gervais et al., 2007; Gervais et al., 
2001). Metal ions have also been suggested to be crucial for the formation of 
fibrils and molecular chelators that would perturb Aβ-metal binding, like 
clioquinol, have been tested (Cherny et al., 2001). 
 
Small molecules can be good drug candidates since they are often orally 
available and can cross the blood-brain barrier. However, a disadvantage 
with being small could be a lack of specificity. Being small only allows these 
inhibitors to recognize and bind limited sized regions that might not be 
found exclusively in the target molecule. This could make them prone to 
interact with various molecules. Another potential problem, especially with 
compounds found by screening of chemical libraries, could be that they 
have an unknown mechanism of action making it more difficult to optimize 
the structure.  
 
Peptide-based inhibitors 
In order to improve specificity, inhibitors based on Aβ segments have been 
developed. Tjernberg et al. were the first to show that the KLVFF motif 
(Aβ16-20) could acts as an inhibitor of full length Aβ aggregation (Tjernberg et 
al., 1996). Soto et al. developed β-sheet breaker peptides based on the 
segment Leu17-Ala21 of Aβ.  They introduced proline-substitutions, that 
would reduce β-sheet propensity of the ligand and interfere with backbone 
hydrogen bonding, and added a charged amino acid at the end to increase 
solubility (Soto et al., 1996). These β-breakers were shown to prevent fibril   31
formation, to be stable in vivo and to penetrate the blood-brain barrier 
(Poduslo et al., 1999). One shorter variant (LPFFD, iAβ5) was also shown to 
clear amyloid plaques in a rat model (Soto et al., 1998). When protected at 
both ends to avoid degradation, iAβ5 reduced cerebral damage and amyloid 
deposition in AD transgenic mice (Permanne et al., 2002). Several groups 
have studied the effect of introducing N-methylated amino acids in peptide 
inhibitors based on the Aβ core region. These peptides form extended 
conformations and when bound to Aβ, the N-methyl substituents prevent 
further inter-strand hydrogen bonding and fibril elongation (Kokkoni et al., 
2006; Zhang et al., 2006; Gordon et al., 2002; Gordon et al., 2001). One 
problem with these approaches is that they often target the later stages of 
aggregation, possibly stabilizing the toxic early aggregates. Recently 
however, Austen et al. have demonstrated the design of peptide inhibitors 
based on the Aβ16-21 sequence, targeting oligomeric species instead (Austen et 
al., 2008).  There have also been attempts to use C-terminal derived 
peptides of Aβ1−42 as potential inhibitors of oligomer formation. Fradinger et 
al. have shown that the Aβ-fragments 31-42 and to some extent 39-42 
potently disrupt oligomer assembly of Aβ1-42 and are able to reduce Aβ-
induced cell toxicity (Fradinger et al., 2008). Another peptide-based 
inhibitor of oligomerization, combining the β-breaker strategy with 
inhibition of aromatic recognition, was recently described (Frydman-Marom 
et al., 2009). This small molecule, D-Trp-Aib, was shown to be orally 
available, inhibit Aβ toxicity towards cells and to improve cognitive 
performance and reduce the plaque load in AD mice. 
1.4  Surfactant protein C 
Human lung surfactant protein C (SP-C) is a highly hydrophobic 
transmembrane peptide consisting of 35 amino acids residues (Beers & 
Lomax, 1995). It is expressed exclusively in alveolar type II epithelial cells 
and is secreted, together with phospholipids and SP-B, into the alveoli 
where it aids in lowering the surface tension at the air-water interface, 
thereby preventing alveolar collapse at end expiration (Whitsett & Weaver, 
2002).    32
 
Figure 8. Schematic view of proSP-C situated in the ER membrane. The N-terminal (green) 
corresponds to residues 1-23 and resides in the cytosol. Residues 24-58 make up the mature 
SP-C (red) and residues 59-197 corresponds to the C-terminal (blue) located in the ER 
lumen. (Figure from Prof. Timothy Weaver)  
SP-C is expressed as a 197-residue integral membrane proprotein (proSP-
C) which is anchored in the endoplasmic reticulum (ER) membrane in a 
type II orientation, i.e. with the C-terminal in the ER lumen (Figure 8). 
The mature peptide is found in the transmembrane region and corresponds 
to residues 24-58. The N-terminal propeptide (residues 1-23) is important 
for the trafficking and stability of the proprotein in the secretory pathway (Li 
et al., 2004; Conkright et al., 2001) whereas the C-terminal domain, CTC 
(residues 59-197), has an unknown function. Expression of proSP-C, 
lacking parts of the C-terminal, results in ER stress, intracellular protein 
aggregation and cytotoxicity which indicate that this region is somehow 
vital for the stability of the proprotein (Mulugeta et al., 2005; Bridges et al., 
2003; Kabore et al., 2001). 
 
Mutations in the SP-C gene are associated with interstitial lung disease  
and cause the protein to misfold and aggregate intracellularly (Nogee et al., 
2002; Thomas et al., 2002; Nogee et al., 2001). Most disease-linked 
mutations found in the proSP-C gene are located in CTC, and specifically 
in a domain known as Brichos, covering residues 94-197 (Beers & 
Mulugeta, 2005). Brichos is a novel domain, consisting of around 100 amino 
acid residues, that has been found in over 100 proteins divided into 11 
families, based on sequence similarity (Hedlund, 2009). These previously   33
unrelated proteins are associated with various functions and some 
degenerative and proliferative disorders e.g. ITM2B (Bri) associated with 
amyloid formation in familial British and Danish dementia (Kim et al., 2000; 
Vidal et al., 2000). The proteins in the Brichos families are all made up of 
four regions, organized in the same manner, starting with a hydrophobic 
stretch followed by a linker region, the Brichos domain and finally a C-
terminal part. The only exception to this structure is proSP-C which lacks a 
C-terminal extension after the Brichos part. Only three residues are strictly 
conserved in the domain; one aspartic acid and two cysteine residues. In 
recombinant CTC, these cysteines form a disulfide bridge (Casals et al., 
2008). Since the Brichos domain clearly exist in various proteins, numerous 
functions have been proposed for it, including a role in post-translational 
processing and a chaperone-like function (Sanchez-Pulido et al., 2002). 
However, up till now there has been no experimental support for such 
functions. 
 
The transmembrane α-helix of SP-C is discordant, i.e. it is composed of 
amino acids with a high propensity to form a β-strand, mostly Val and Ile 
(Kallberg et al., 2001). These amino acids are branched at the β-carbon 
which disfavors α-helix formation, making the helix less efficient in folding. 
For this reason, although stable once folded and inserted into the membrane, 
the region is unstable in solution and when unfolded it doesn’t retain its 
structure but will spontaneously convert to β-sheet aggregates and to 
amyloid-like fibrils (Szyperski et al., 1998). Fibrils of SP-C have been 
isolated from patients with the lung disease pulmonary alveolar proteinosis, 
adding SP-C to the list of proteins capable of forming amyloid-like fibrils 
(Gustafsson et al., 1999).    35
2  Present investigation 
2.1  Scope of this thesis 
The overall aim of this thesis was to study ways of affecting protein 
misfolding and subsequent formation of amyloid-like fibrils, with emphasis 
on Aβ. 
 
In particular we performed studies aimed to: 
 
   Investigate the possibility to stabilize the helical structure of Aβ, using 
small designed ligands, in order to prevent amyloid fibril formation and 
toxicity (paper I-II). 
 
   Elucidate the role of CTC, and its Brichos domain, in the folding and 
stabilization of proSP-C and mature SP-C (paper III). 
 
   Characterize the binding specificity of CTC and investigate its potential 
role as a general anti-amyloid chaperone (paper IV-V). 
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2.2  Methods 
In the following section some of the methods used in this thesis are 
summarized. Detailed descriptions of the experimental procedures can be 
found in the respective papers 
 
2.2.1  Transmission electron microscopy 
Transmission electron microscopy (TEM) is a powerful technique based on 
the same principles as light microscopy that uses electrons instead of light. 
The resolution of light microscopy is limited by the wavelength of light but 
by using a focused beam of electrons, with lower wavelength, the resolution 
can be improved around a thousand times, yielding a magnification up to 
500,000-1,000,000 times. Briefly, a beam of electrons is passed through the 
specimen of interest and the interactions with the molecules in the sample 
will cause some of the electrons to scatter. The unscattered part of the beam 
will create patterns on the detection plate that correspond to the densities of 
various parts of the sample where darker areas indicate electron dense parts.  
 
For TEM analysis the sample needs to be thin enough to allow the 
electrons to pass and contain molecules that diffract electrons. Biological 
samples are composed mainly of atoms of low electron density (e.g. carbon, 
hydrogen and nitrogen) and will therefore allow most electrons to pass 
undisturbed, resulting in poor contrast. In order to improve contrast, 
negative staining of the samples can be employed. The stains used are usually 
heavy metal salts, e.g. uranyl acetate, which will easily interact with the 
electron beam. The stain will not bind to the sample but will instead 
surround it so that the edges of the specimen will absorb most electrons – in 
the end creating a “negative” image. 
 
2.2.2  Circular dichroism spectroscopy 
Circular dichroism (CD) spectroscopy is a technique that makes use of the 
fact that chiral molecules will interact differently with right- and left-
circularly polarized light (Woody, 1995). Peptides and proteins have chiral 
properties and contain a number of groups with characteristic absorption 
patterns, chromophores, with the main chromophore in far-UV CD (< 
250nm) being the amide group in the peptide bond.   
 
The sample to be analyzed is illuminated with plane polarized light, 
which consists of right- and left-circularly polarized beams of light with the   37
same intensity (Figure 9A). The chiral molecules will absorb the two beams 
to different extent and due to this phenomenon the outgoing light will be 
converted into elliptically polarized light (Figure 9B). 
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Figure 9. Circular dichroism spectroscopy. A) The light reaching the sample consist of two 
circularly polarized light-beams with different rotations (left and right circularly polarized) – 
making up the plane polarized beam (red arrow). B) When the light passes through the 
sample the two components will be absorbed differently and the outgoing light will be 
elliptically polarized (red arrow). C) Ellipticity (θ) is defined as the indicated angle in the 
resulting ellipse and describes the degree of circular dichroism. 
CD is defined as the difference in absorption (A) of right (R) and left (L) 
circularly polarized light 
 
CD(λ) = AL(λ) – AR(λ) 
 
Ellipticity, defined as the angle θ (Figure 9C), is a normal quantity used 
for describing the degree of circular dichroism. θ can be related to ΔA 
according to: 
 
            θ = 32.98 (AL-AR) 
 
Usually spectra are reported using mean residual molar ellipticity ([θ], 
unit: kdeg x  cm
2  x  dmol
-1) in order to remove the dependence of path 
length (l), concentration (c) and number of amino acid residues (n): 
  
[θ] = 100θ/(c · n · l) 
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CD can be used for estimation of secondary structure elements as well as 
for monitoring conformational changes, e.g. from denaturation or ligand 
binding. Different secondary structure elements give rise to specific patterns 
when the molar ellipticity is plotted against wavelength. Figure 10 
summarizes the characteristics of CD spectra obtained from proteins with 
different secondary structures.  
 
Figure 10. Characteristic circular dichroism spectra of proteins with α-helical (α), β-sheet (β) 
or random-coil (r) structures. 
2.2.3  Mass spectrometry 
Mass spectrometry (MS) is a technique for measuring the mass of a 
molecule, that can be used for characterizing proteins and peptides. The 
outline of a MS instrument is briefly as follows; the sample of interest is first 
introduced, ionized and transferred into the gas-phase in an ion source, the 
produced ions are separated in vacuum according to their mass-to-charge 
ratio (m/z) in a mass analyzer and are thereafter detected in a detector 
(Edmond de Hoffman, 2002).  
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The problems associated with transferring large biomolecules, such as 
proteins and peptides, into the gas-phase were resolved when two soft-
ionizations techniques were introduced in 1987-1989: matrix-assisted laser 
desorption/ionization (MALDI) (Karas & Hillenkamp, 1988) and 
electrospray ionization (ESI)(Fenn et al., 1989). Using these techniques, 
briefly described below, fragmentation can be avoided and multiple charges 
can be imposed on molecules which will lower the m/z ratio making them 
easier to detect. 
 
Matrix-assisted laser desorption ionization  
In the MALDI process the sample is first co-crystallized with a light-
absorbing solution, often a weak aromatic acid, called a matrix. The formed 
crystals containing both sample and matrix are thereafter irradiated with a 
laser. The matrix molecules will absorb the energy of the laser resulting in 
vaporization and expansion of the matrix into the gas-phase taking the 
sample molecules with it. In the gas-phase, protons are transferred from the 
matrix molecules to the sample creating ions that can be separated and 
detected. This technique yields mainly singly-charged ions and few 
fragments. It is compatible with non-volatile solvents and is less sensitive to 
contaminating compounds compared to ESI.  
 
Electrospray ionization 
In ESI the sample solution is pumped through a capillary over which a 
strong electric filed is applied, creating a “spray” of charged droplets at the 
tip of the capillary. On the way to the mass spectrometer the solvent 
evaporates from the droplets creating a cascade of ruptures due to the charge 
concentration, yielding even smaller highly charged droplets. This process 
will finally result in the release of charged analyte molecules that can then be 
analyzed. The analyte molecules generally receive their charge through gas-
phase proton-transfer. This technique requires the use of volatile solvents, 
results in very little fragmentation and yields multiple-charged ions, making 
detection of large molecules easier. 
 
2.2.4  Fluorescence spectroscopy 
Fluorescence is a form of luminescence, the emission of photons from 
electronically excited states. It utilizes the fact that some molecules, 
fluorophores, can be excited from their ground state to a higher energy state,   40
called an excited state, via absorption of light. This higher energy state is 
unstable and when the molecule returns to the ground state again a photon 
with a different wavelength (lower energy) is emitted and can be measured 
(Lakowicz, 1983). 
 
Intrinsic fluorescence 
In proteins and peptides the aromatic side chains of tyrosine, tryptophan and 
phenylalanine are intrinsic fluorophores. Of the three, tryptophan exhibits 
the highest fluorescent yield whereas the other two are weaker emitters in 
comparison. The emission spectra of proteins are sensitive to binding of 
substrates, protein-protein interactions and denaturation and changes in 
intrinsic fluorescence can be used to study structural changes (Lakowicz, 
1983). In this thesis Trp-fluorescence was employed to study the ligand-Aβ 
interactions with the Trp-containing ligand used in paper II. For this 
purpose exitation at 280 nm was used and emission was observed between 
290 and 400, with a peak at 348 nm. 
Thioflavin T fluorescence 
Thioflavin T (ThT), a cationic benzothiazole dye, is widely used for the 
detection of amyloid fibrils both in solution and in tissue. Upon binding to 
amyloid fibrils, this dye exhibits an enhanced fluorescence with an emission 
maximum at 482 nm and a new absorption peak at 450 nm (LeVine, 1993). 
The mechanism behind this phenomenon and the exact structure that ThT 
binds to is not clear. It has been suggested that the dye, with a hydrophobic 
part linked to the polar benzothiazole group (Figure 11), could form 
micelles in aqueous solution and that binding of these micelles to the fibrils 
would cause the change in fluorescence (Khurana et al., 2005). Binding of 
monomeric ThT to channels within the β-sheet of the fibrils has also been 
suggested (Krebs et al., 2005).  
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Figure 11. Molecular structure of Thioflavin T.   41
2.2.5  Model systems 
Drosophila melanogaster model 
For paper I a Drosophila melanogaster model of Aβ1-42 aggregation generated 
by Crowther et al. (Crowther et al., 2005) was used. This transgenic strain 
express two gene copies coding for human Aβ1-42, one on chromosome 2 
and one on chromosome 3. The genes code for Aβ1-42 coupled with a 
secretion signal peptide to direct the synthesis of Aβ to the ER. The 
UAS/Gal4 activation system (Brand & Perrimon, 1993) was used in order
to control gene expression. The final transgenic strain was obtained by
crossing transgenic Aβ flies with flies transgenic for the Gal4-elav
c155
  pan-neuronal driver (Lin & Goodman, 1994), which will drive Aβ1-42  
production in the CNS and retina of the fly. The expression and 
accumulation Aβ in the transgenic flies resulted in an observed reduction of 
locomotor activity as well as a reduced lifespan compared to non-transgenic 
flies. 
 
Cell models 
For this thesis two different cell models were used. For the aggregation 
studies in paper III human embryonic kidney cells (HEK293) were used and 
for the toxicity studies in paper I and II we used PC12 cells. HEK293 is a 
commonly used cell line generated by transformation of a human embryonic 
kidney cell line with DNA from human adenovirus type 5 (Graham et al., 
1977). PC12 is a cell line derived from a rat pheochromocytoma, a tumor of 
the adrenal medulla, which has a neuroectodermal origin (Greene & 
Tischler, 1976). PC12 cells are often used as a model system in 
neurobiology and neurochemistry and will, when grown in the presence of 
nerve growth factor (NGF) extend neurites and increase the synthesis of a 
number of neurotransmitters – similar to neuronal differentiation. However, 
in paper I and II, undifferentiated PC12 cells were used since these cells are 
known to be sensitive to Aβ induced toxicity. 
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2.3  Results and discussion 
2.3.1  α-Helix targeting reduces amyloid β-peptide aggregation and toxicity 
There is no consensus in the AD field as to which intermediate species on or 
off the fibrillation pathway that are truly neurotoxic. However, it is likely 
that misassembly of Aβ play a role in the disease. From this perspective 
targeting intermediates might result in the accumulation of toxic assemblies. 
In light of this, we set out to find a way of stabilizing the native monomeric 
structure of Aβ, thereby preventing misfolding and aggregation. This 
strategy has been employed for other aggregation prone proteins such as 
superoxide dismutase (SOD) (Ray et al., 2005; Ray & Lansbury, 2004) and 
the amyloidogenic transthyretin (Hammarstrom et al., 2003; Miroy et al., 
1996) where stabilization of a native dimer or tetramer, respectively, 
prevented dissociation into monomers and aggregation. The approach, 
termed native state stabilization, means that the folded state is selectively 
stabilized over the un/misfolded state, which will raise the barrier for 
unfolding. 
 
It has been argued that the concept of native state stabilization would not 
be applicable to intrinsically disordered peptides and proteins like Aβ. 
However, Aβ shows secondary structure propensities in its C-terminal and 
middle regions, especially in stabilizing environments like membranes. It 
contains a discordant helix covering residues 16-23 and this helical structure 
probably needs additional support when it loses its stabilizing interactions 
after release from the membrane environment (Paivio et al., 2004; Kallberg 
et al., 2001). It has recently been proposed that stabilization of helical 
structures in Aβ1-40 as well as Aβ1-42 would block oligomerization by 
preventing the conversion into β-structure (Yang & Teplow, 2008).  
 
Using molecular modeling two classes of molecules, targeting and 
stabilizing the discordant helix of Aβ, were designed (papers I-II). One 
class included the peptoids Pep1a, Pep1b and Pep2. The other class 
consisted of four decanoyl polyamines; Dec-DETA, Dec-TETA, Dec-
DPTA and Dec-Spermine. All of the compounds were designed to interact 
with hydrophobic patches and charged amino acid side chains in the 13-23 
region of Aβ, residues that could potentially destabilize the helix. For 
structures and proposed modes of interaction, see Figure 12.   43
 
 
Figure 12. Structures of ligands designed to stabilize the 13-23 region of Aβ in a helical 
conformation. The proposed interactions are indicated. 
In paper I, Pep1a, Pep1b and Dec-DETA were evaluated and found to 
potently affect the aggregation and fibril formation of Aβ1-40 in vitro. The 
peptoids reduced fibril formation whereas Dec-DETA induced formation of 
shorter and thicker fibrillar species that exhibited an unexpected increase in 
ThT-fluorescence. All three ligands were able to stabilize a helical 
conformation in fragments of Aβ harboring the discordant helix. The 
interactions observed were sequence dependent since no structural changes 
were seen when the ligands were added to a scrambled version of Aβ13-23. In   44
an MTT-assay, using the PC12 cell line, the ligands reduced Aβ1-42 induced 
toxicity and they also had the ability to prevent reduction of γ-oscillations, 
associated with Aβ in mouse hippocampal slices. Measuring 
electrophysiological functions such as γ−oscillations is a good way of 
determining the toxic effect of Aβ since they are important for memory and 
cognition (Engel & Singer, 2001) and are markedly reduced in Alzheimer´s 
patients (Ribary et al., 1991). To evaluate the oral availability and the 
potency of our ligands to affect Aβ aggregation in vivo, Pep1a and Dec-
DETA were administered to Drosophila melanogaster expressing Aβ1-42 in their 
CNS. An improvement in longevity and mobility, in combination with a 
reduction in nervous tissue destruction, was observed in the treated flies. 
The specificity of the ligands was tested by administering them to wild-type 
flies and flies expressing mutant huntingtin, an aggregation-prone protein 
linked to Huntingtons disease. No rescuing effect was observed in these flies, 
verifying the Aβ specificity of the designed compounds. Together these data 
suggest that stabilizing the discordant helix of Aβ with small designed ligands 
is a possible therapeutic strategy to prevent misfolding and toxicity. 
 
Since the concept of native state stabilization seems to work for Aβ 
(paper I), we expanded the design and synthesis of ligands (paper II) to 
investigate how small structural changes would affect the interactions. One 
new peptoid, Pep2, and three additional decanoyl polyamines, Dec-TETA, 
Dec-DPTA and Dec-Spermine, were evaluated. Pep2 proved to be as 
efficient as Pep1 in preventing fibril formation, it induced helical 
conformation in Aβ-fragments containing the 16-23 region and bound to 
helical Aβ13-23 as judged by fluorescence spectroscopy. It also reduced Aβ1-42 
induced cell toxicity in PC12 cells. However it did not reduce ThT-
fluorescence as might be expected from the observed decrease in fibril 
formation. It is possible that Pep2 promotes the formation of Aβ-oligomers 
capable of ThT-binding with a reduced cell-toxicity compared to species 
formed in solutions of Aβ alone. The three decanoyl derivatives all stabilized 
a helical conformation in Aβ-fragments with specificity and reduced ThT 
fluorescence by 50 %. Using ESI-MS they were shown to bind full-length 
Aβ1-40 and they affected fibril formation to varying degrees with Dec-
Spermine being the most potent inhibitor as judged by TEM. In cell-assays 
all three decanoyl derivatives reduced Aβ1-42 cell toxicity, with Dec-DPTA 
showing the most prominent reduction. 
 
Small molecules targeting Aβ and preventing amyloid-like fibril 
formation has been reported on extensively. However most act by unknown   45
mechanisms and probably with low specificity. Here we show that by 
targeting the central helix of Aβ it is possible to generate Aβ-specific, orally 
available compounds with an inhibitory effect on aggregation. A problem 
with some known inhibitors of fibril formation, recently pointed out, is that 
they also function as chemical aggregators and that this is the basis of their 
inhibitory effect (Feng et al., 2008). This, however, was shown not to be the 
case for these ligands.  
 
The compounds presented in papers I and II should be seen as starting 
points for further optimization. The fact that small structural changes are 
allowed, without affecting the activity of the ligands, indicates there is a 
degree of freedom in designing new compounds as long as the basic 
requirements of the concept are met. 
 
2.3.2  Novel chaperone with anti-amyloid properties 
SP-C is a transmembrane protein, with a poly-Val helix prone to misfold, 
that have been shown to form amyloid-like fibrils. The protein is expressed 
as a proprotein, proSP-C, with a C-terminal part, CTC, which contains a 
Brichos domain, suggested to have a chaperone-like function. This proposed 
function for the Brichos domain, together with the fact that a number of 
mutations in CTC have been linked to interstitial lung disease lead us to 
investigate the function of this C-terminal propeptide. 
 
In paper III, we show that CTC binds to mature SP-C only when it is 
in a non-helical conformation and that it has the ability of preventing SP-C 
from forming amyloid-like fibrils in vitro.  To study the effect of CTC on 
the folding and stability of the proprotein, witldtype proSP-C and proSP-C 
with three different mutations linked to disease, I73T, L188Q and ΔExon4, 
were expressed individually in HEK293 cells. Only the mutations located in 
the Brichos domain, i.e. L188Q and ΔExon4, resulted in aggregation and 
formation of amyloid-like deposits. Co-expressing CTC (carrying an ER-
retention signal) with proSP-C
L188Q abolished amyloid formation and it was 
shown that CTC binds mutant proSP-C in significantly higher degree than 
wildtype proSP-C. These data indicate that CTC is important for the 
stabilization and correct folding of the proprotein in the ER and that its 
activity is most likely linked to the Brichos region. Replacing the 
transmembrane poly-Val segment in the proprotein with a poly-Leu stretch, 
which has a higher α-helix propensity, stabilizes proSP-C
L188Q indicating that 
it is the transmembrane region that drives aggregation. Together these results   46
implicate an anti-amyloid role for CTC as an intramolecular chaperone. We 
propose that CTC, via the Brichos domain, stabilizes the transmembrane 
poly-Val region of proSP-C until it has attained its correct fold, thereby 
preventing aggregation and amyloid formation of this unusually 
hydrophobic and folding-incompetent protein. Intramolecular chaperones 
and pro-sequence assisted folding have been found for a number of proteins, 
such as subtilisin (Ikemura et al., 1987) and carboxypeptidase Y (Winther & 
Sorensen, 1991). The chaperone activity in these is usually located to the C- 
or N-terminal extensions in the proprotein (Chen & Inouye, 2008). From 
our data it seems possible that CTC can exert its function either 
intramolecularly or in trans, on neighboring proteins, like a molecular 
chaperone. 
 
In an attempt to further characterize the function of CTC and especially 
the substrate specificity and requirements for binding, a SPOT analysis was 
performed (paper IV).  Using SPOT membranes with bound decamers of 
amino acids it was shown that CTC specifically recognises and binds to 
residues that promote membrane insertion, according to the “biological 
hydrophobicity scale” (Hessa et al., 2005). Transmembrane regions need to 
expose nonpolar sidechains and hide their polar backbone in order to fit 
inside cellular membranes. Consequently, membrane insertion is promoted 
by the presence of the amino acids Ile, Leu, Phe and Val and also by a α-
helical conformation (Hessa et al., 2005). In paper IV it is also shown that 
CTC is able to distinguish between target peptides that are in different 
conformations, binding only to β-strand conformations – in line with 
previous observations (paper III and (Johansson et al., 2006)). These data 
imply that CTC can recognise and bind to transmembrane segments that 
have not yet folded into the required α-helical conformation, acting in a 
chaperone-like manner. This proposed function fits well with the fact that 
proSP-C has a transmembrane segment, mainly consisting of Val, with an 
instrinsic prodisposition to misfold that needs assistance to avoid misfolding 
and formation of amyloid-like fibrils. 
 
General properties of transmembrane proteins overlap to some extent 
with the proposed main determinants for amyloid formation, including 
hydrophobicity and overall charge. Initial studies (paper IV) showed that 
the anti-amyloid function of CTC found for SP-C extends to Aβ1-40, which 
also contains a transmembrane helix. In paper V the interaction between 
CTC and Aβ1-40 was further explored and the ability of CTC to act as a 
chaperone for amyloidogenic peptides was evaluated. It was shown that   47
CTC keeps Aβ1-40 in a soluble form and potently inhibits it from aggregating 
and forming amyloid-like fibrils in a substoichiometric ratio, but is unable to 
dissociate pre-formed fibrils. However, CTC did not show classic chaperone 
activity, again pointing to the possibility that it is a chaperone targeting 
specific types of proteins only. Aβ1-40 and CTC formed stable complexes that 
allowed for SEC and ESI-MS studies. Using SEC a complex of 110 kDa, 
possibly corresponding to a 12-mer of Aβ1−40 together with a CTC trimer, 
was found. This in line with previous findings showing that CTC 
preferentially forms trimers in solution (Casals et al., 2008). Stable 12-mers 
of Aβ has also been reported on (Lesne et al., 2006; Barghorn et al., 2005). 
The ESI-MS experiments however, indicated that the dominating species 
would be a CTC trimer bound to monomeric Aβ. Taken together, the data 
suggests that complexes are formed between a CTC trimer and an Aβ 
molecule, possibly present in a 12-mer assembly. CTC was also found to 
prevent the amyloidogenic protein medin from forming amyloid-like fibrils 
indicating that CTC might possess a more general anti-amyloid activity.  
 
In conclusion, we propose that CTC, possibly via its Brichos domain, has 
the ability of acting as a chaperone, recognizing unfolded transmembrane 
segments and stabilizing them until they have obtained their correct fold. 
This function, which to our knowledge has not been observed for any other 
protein, probably originates from the fact that proSP-C is highly aggregation 
prone and in need of folding-assistance. It is also possible that this ability is 
coupled with a more general anti-amyloid function that could be applicable 
to other non-transmembrane and/or amyloidogenic proteins. Recently, 
extracellular chaperones have been implicated in the prevention of amyloid 
fibril formation. In light of this, the properties described here make CTC, 
and especially the Brichos domain which is found in other pro-proteins as 
well, interesting from a diagnostic and therapeutic perspective. Brichos 
domains have been found in other pro-proteins associated with amyloid 
formation like the Bri protein. The possibility of using this new, naturally 
occurring, chaperone to prevent the formation of toxic amyloid assemblies 
needs to be further explored.    49
3  Concluding remarks 
Folding of proteins remains an important but incompletely understood 
process. Misfolding and aggregation of proteins is linked to a large number 
of diseases, causing problems due to loss of function or, in the case of 
amyloid disorders, gain of toxic function. A number of natural mechanisms 
that prevent misfolding and misassembly exist and include e.g. localization of 
charged residues in edge β-strands to prevent β-sheet formation (Richardson 
& Richardson, 2002) and structural gatekeepers in the form of charged 
residues which interrupt stretches of hydrophobic residues and thereby 
prevent unwanted interactions (Otzen et al., 2000). In addition, molecular 
chaperones aid in the folding process.  
 
Amyloid fibrils are insoluble aggregates, formed by a number of proteins 
and are linked to various diseases. For aggregation to occur, globular 
proteins most likely need to be destabilized and partially unfolded whereas 
disordered proteins, such as Aβ, need to obtain partial order similar to that 
found in the aggregates, i.e. β-strands for amyloid fibril formation. It has 
been suggested that Aβ can exist as a β-hairpin prior to aggregation which is 
in line with this assumption. The kinetics of misfolding and misassembly are 
likely to be of importance and small changes in the rate of aggregation could 
prove to be very beneficial in misfolding diseases. With this in mind, 
stabilization of the native state or reducing the amount of protein produced 
seems like a natural place to start in the search for therapeutic approaches. 
 
In this thesis two strategies for preventing misfolding and amyloid 
formation are presented and evaluated. One utilizes the concept of native 
state stabilization with the aid of small designed molecules targeting the 
discordant  α-helix of Aβ and the other involves a naturally occurring   50
chaperone with affinity for unfolded transmembrane segments, that has 
proved to exhibit anti-amyloid properties. 
 
Using rationally designed compounds, to target the helical region of Aβ, 
will most likely improve the specificity compared to compounds found by 
screening of large libraries. The compounds described in this work should 
be viewed as support of a novel strategy of inhibition. In order to be 
considered as potential drug candidates, the structures need to be adjusted to 
further improve specificity and affinity. Protease resistance and ability to 
efficiently cross the blood-brain-barrier are also important characteristics that 
need to be considered. However, the initial studies made are encouraging. 
 
Data on Aβ, its aggregation and the connection to Alzheimer´s disease, 
are confusing. Numerous oligomers and intermediates on or off the 
fibrillation pathway have been reported and shown to induce cell toxicity 
and memory impairment. To further complicate the matter there are no 
clear data on how Aβ exerts its toxicity, or which species that are involved 
in the in vivo situation. It cannot be ruled out that there are other key players 
in the disease, besides Aβ and its precursor protein, that are yet to be found. 
Establishing which, if any, of the soluble Aβ species observed that are 
actually relevant for the disease is a challenging and important task, especially 
for the future development of therapies. Stabilizing a monomeric peptide 
rather than targeting later stages of the aggregation could eliminate the risk 
of accumulating harmful oligomers. In a membrane environment, Aβ 
exhibit helical structure in two regions, that are later involved in the 
formation of β-sheets. The conversion from a α-helical to β-strand 
conformation has been proposed to be essential for fibril formation. 
Stabilizing helical conformation, in at least one of the two regions of Aβ 
forming strands in the fibrils, could prevent toxic aggregation as shown in 
this thesis. 
  
Besides native structure stabilization, removal of different types of 
aggregates could also be a successful strategy in misfolding disorders. An 
approach that has the potential of accomplishing both of these tasks is the 
use of chaperones. It is possible that a decline in chaperone activity with age 
may be a major contributing cause in diseases associated with protein 
aggregation and deposits thereof. Studies presented in this thesis show the 
existence of a chaperone, CTC, which inhibits fibril formation of 
amyloidogenic proteins. CTC, containing a Brichos domain, has most likely 
evolved to prevent misfolding and subsequent aggregation of a highly   51
hydrophobic, folding incompetent, part of proSP-C. Unlike molecular 
chaperones, that display little substrate specificity, CTC recognizes elongated 
stretches of nonpolar amino acid residues with high specificity. If this 
specificity and chaperone activity apply to other Brichos domains, needs to 
be investigated. Solving the structure of CTC might shed more light on the 
mechanism by which it acts, possibly revealing the region involved in 
binding.  
 
The ability of CTC to act in a chaperone-like manner towards 
amyloidogenic proteins is intriguing. A plausible explanation for its activity 
is outlined in Figure 13. Briefly, CTC recognizes elongated conformations 
of peptides containing primarily the amino acid residues Val, Ile, Leu and 
Phe. Binding to these segments will inhibit further aggregation and possibly 
allow for re-folding (Johansson, 2009). This function might also include an 
ability to bind to soluble aggregates, which expose CTC-binding epitopes, 
and promote their uptake and degradation by nearby cells, like extracellular 
chaperones. If so, this would clearly be a promising lead and deserves to be 
investigated further. 
 
 
Figure 13. Proposed mode of action of CTC. 
Interacting with and stabilizing native states of proteins prone to misfold 
is a tempting and highly conservative strategy, preventing disease associated 
events as early as possible. This is especially true for situations where the 
mechanism of toxicity is poorly understood, like the role of Aβ in 
Alzheimer´s disease. The two novel strategies outlined in this thesis can both 
target monomeric states of aggregation-prone proteins. In addition, if the   52
chaperone-like activity towards amyloidogenic proteins of CTC can 
eliminate early aggregates as well, it could be possible to use CTC as a 
starting point of new chaperone-based therapeutics in the field of misfolding 
diseases. 
 
An interesting difference between the two types of compounds described 
in this thesis, α-helix targeting ligands and CTC, is their origin. CTC has 
evolved naturally probably due to a need for folding assistance whereas the 
ligands are an attempt on our behalf to control a naturally occurring event. 
The efficiency and applicability of the two strategies remains to be seen, but 
it is tempting to suggest that CTC, due to its origin, might show a better 
specificity and affinity than the designed ligands. However the size and the 
fact that it is a protein could prove problematic in terms of crossing the 
blood-brain-barrier and being stable in novel environments. From this 
perspective, small man-made ligands have a clear advantage in that they can 
more easily be manipulated and targeted towards specific locations. So the 
intriguing question remains – can we control nature better than nature itself? 
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Fredrik och Maria – ni är underbara! Tack för all hjälp ni ger oss, nu finns 
all tid i världen för fika ☺ 
Mamma och pappa – tack för att ni alltid finns där, alltid tror på mig och 
alltid orkar lyssna! 
 
Anton, min illbatting – du och din entusiasm gör livet ljusare och härligare! 
Petter, oh captain my captain – tack för ditt tålamod och din aldrig sinande 
optimism. Du gör mig till en bättre person  - jag älskar dig!    55
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